Purpose: Multiparametric magnetic resonance imaging and fusion biopsy detect more high risk prostate cancer and less low risk prostate cancer than systematic biopsy. However, there remains a small subset of patients in whom systematic biopsy captures higher grade disease than fusion biopsy. We sought to identify potential mechanisms of the failure of fusion biopsy in the detection of clinically significant prostate cancer. Materials and Methods: We reviewed a prospectively maintained database of patients who underwent multiparametric magnetic resonance imaging followed by fusion biopsy and systematic biopsy from 2007 to 2014. In patients in whom disease was upgraded to clinically significant disease (Gleason 7 or greater) by systematic biopsy over fusion biopsy, independent re-review of magnetic resonance imaging, archived biopsy imaging and whole mount pathology as well as needle coordinate mapping were performed. Multivariate logistic regression analysis was done to determine predictors of upgrading by systematic biopsy. Results: Disease was upgraded based on systematic biopsy over fusion biopsy in 135 of 1,003 patients (13.5%), of whom only 62 (6.2%) were upgraded to intermediate (Gleason 7) and high risk (Gleason 8 or greater) prostate cancer (51 or 5.1% and 11 or 1.1%, respectively). On multivariate analysis lower prostate specific antigen (p <0.001), higher magnetic resonance imaging prostate volume (p <0.001) and a lower number of target cores (p ¼ 0.001) were predictors of upgrading by systematic biopsy. Main mechanisms of under grading by fusion Accepted for publication August 19, 2016. No direct or indirect commercial incentive associated with publishing this article. The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.
PROSTATE specific antigen based screening paradigms and TRUS guided SBx have resulted in over diagnosis and overtreatment of low risk PCa. The addition of functional sequences in mpMRI has improved PCa detection while FBx has facilitated targeted biopsy of suspicious lesions. 1 FBx now has a well-defined role in patients with prior negative TRUS biopsies and lesions in areas traditionally under sampled with SBx. 2e5 Furthermore, FBx identifies more high risk cases while avoiding detection of clinically insignificant low risk cancers. 6e8 Nevertheless, there remains a small subset of patients in whom SBx captures higher grade disease than FBx. This is especially critical when CS cancer is found on SBx and missed by FBx with previous studies suggesting rates ranging from 3.5% to 13%. 9e11 The reasons by which FBx misses disease identified by SBx are not clearly understood and have not been fully investigated.
In the current study we sought to identify predictors of disease upgrading by SBx over FBx and define potential mechanisms by which FBx fails to capture CS disease.
MATERIALS AND METHODS

Study Population
We retrospectively reviewed the records of 1,003 consecutive patients who underwent FBx for elevated PSA or abnormal DRE at NCI (National Cancer Institute), NIH (National Institutes of Health) from 2007 to 2014. All patients were enrolled in an institutional review board approved, prospective trial of mpMRI and FBx (ClinicalTrials.gov NCT00102544). Only initial biopsy sessions were included for analysis in patients with multiple biopsies during the study period. This cohort has been reported previously 9, 12 but the current objective and analysis have not been published.
Image Acquisition and Interpretation
Patients underwent diagnostic 3.0 Tesla mpMRI using an Achieva device (Philips Healthcare, Andover, Massachusetts) with a 16-channel SENSE surface coil (Philips Healthcare) positioned over the pelvis and a BPX-30 endorectal coil (MedradÒ). mpMRI included triplanar T2-weighted, diffusion-weighted images with apparent diffusion coefficient mapping, high b value diffusionweighted MRI (b ¼ 2,000 seconds per mm 2 ) and dynamic contrast enhanced images. Lesion location, MRI SS (scale 1 to 5) and tumor diameter were recorded. All mpMRI studies were prospectively evaluated by 2 genitourinary radiologists (BT and PLC) with 8 and 16 years of experience with prostate imaging, respectively.
Biopsy Protocol
Patients with suspicious lesions on mpMRI underwent FBx using an office based UroNav platform (Philips/ In Vivo, Gainesville, Florida). T2-weighted images were segmented and co-registered via rigid registration with real-time TRUS images during biopsy. Suspicious lesions were shown as centroid targets and sampled in axial and sagittal planes, generating 2 biopsy cores per target. 13 This was directly followed by SBx at the same biopsy session. Specimens were reviewed by a single genitourinary pathologist (MJM) with 26 years of experience.
Study Design
Patients upgraded to higher risk disease based on SBx were identified by biopsy pathology. Low risk disease was defined as Gleason 6 (3 þ 3), intermediate risk disease was defined as Gleason 7 (3 þ 4 and 4 þ 3) and high risk disease was defined as Gleason 8 (4 þ 4) or greater. CS PCa was defined as Gleason 7 or greater. In this subset of patients independent nonblinded review of imaging was repeated to determine an overlap of target(s) previously identified by mpMRI and sextant from SBx, which revealed higher risk disease. Sextant overlap was defined as the presence of a suspicious lesion with subsequent FBx within the same sextant that revealed higher risk disease on SBx. In patients without overlap review of imaging in the sextant that revealed higher risk disease on SBx was repeated to determine whether a lesion was missed on initial review.
Biopsy mapping of tracked needle coordinates was performed in all 25 patients with sextant overlap in whom biopsy was done after October 2011, at which point biopsy mapping capability was integrated into the fusion guided biopsy system, and in whom disease was upgraded to CS disease by SBx over FBx.
The biopsy mapping process was previously described.
14 Briefly, the position of each biopsy specimen was annotated onto T2-weighted MRI by transposing the distal and proximal coordinates of the needle track from TRUS to MRI. Each biopsy core was modeled as a cylinder 4 mm in diameter and 16 mm long, which represented the expected location of the biopsy core. Furthermore, in this subset of patients archived imaging at the time of needle deployment was reviewed to determine the presence of registration and/or mechanical error. Archived imaging included the storage of cine recordings and still image captures throughout the entire procedure for each target. Registration error was defined as inaccurate superimposition of real-time TRUS imaging onto preacquired MRI. Mechanical error was defined as sampling outside the defined centroid bull's-eye.
Re-review of whole mount pathology was performed in the 13 of 25 patients who underwent radical prostatectomy to correlate biopsy pathology from SBx and FBx.
Statistical Analysis
Statistical analysis was performed using IBMÒ SPSSÒ, version 21 
Magnetic Resonance Imaging Review
Of 62 patients upgraded to CS disease 44 (71.0%) had a lesion identified on mpMRI with subsequent FBx in the same sextant that revealed intermediate or high risk disease from SBx. MRI SS was low in 8 cases, moderate in 28, moderate-high in 2, high in 5 and not reported in 1. Tumor diameter was 0.5 to 1 cm in 23 cases, 1.1 to 1.5 cm in 14 and 1.6 to 2 cm in 7. In the remaining 18 of 62 patients (29.0%) mpMRI failed to identify a targetable lesion within the sextant from SBx. On imaging re-review of these 18 cases by an expert genitourinary radiologist 8 were found to have a lesion missed on initial review within the same sextant. MRI SS was low in 3 cases, low-moderate in 1 and moderate in 4. Tumor diameter was 0.5 to 1 cm in 5 cases and 1.1 to 1.5 cm in 3. The remaining 10 patients had no visible lesion within the sextant (MRI invisible findings). 
DISCUSSION
Current PCa detection strategies have limitations. Exploration of novel biomarkers, genomic analysis and imaging has been used to bridge the deficiency. 15e17 Although mpMRI and FBx are significant improvements over the status quo, in a small number of patients they reveal a falsenegative finding that is captured on SBx. The current study represents a comprehensive investigation of identifying potential mechanisms by which FBx under grades CS disease. As expected, lower PSA, higher MRI prostate volume and a lower number of target cores were predictors of upgrading to higher risk disease based on SBx over FBx. Shakir et al found that the diagnostic utility of FBx is greatest in patients with higher PSA while at lower PSA thresholds SBx resulted in greater detection of low risk disease. 18 Therefore, the lower PSA average in the cohort upgraded by SBx likely reflects the finding that most instances of upgrading by SBx were due to the detection of Gleason 6 cancers.
Walton Diaz et al identified an increased yield of PCa detection for FBx compared to SBx in patients with a larger prostate volume and yet also noted a consistent downward trend of the cancer detection rate as prostate volume increased. 19 It is conceivable that FBx accuracy is impacted by enlarged prostates due to increased operator dependent deformation during the biopsy procedure, resulting in registration error. Alternatively, the heterogeneous nature of the transition zone on mpMRI presents a diagnostic challenge and transition zone cancers may be mischaracterized. Despite representing a small proportion overall, it is important to delineate the mechanisms by which FBx missed CS disease. Cash et al examined 61 patients in whom SBx detected cancer when FBx did not. 20 They proposed a failure of FBx technique and a falsely high initial PI-RADSÔ score as the mechanisms of a negative FBx. However, the lack of needle tracking and biopsy mapping to further classify failure of the FBx technique were limitations.
In the current study we reviewed biopsy core mapping of both SBx and FBx cores in 25 of 44 cases that were upgraded to CS disease. We also assessed whole mount histopathological specimens in patients who underwent radical prostatectomy. Biopsy mapping allows for accurate documentation of biopsy locations, rebiopsy of specific sites and focal therapy planning. 21e23 We propose 4 potential mechanisms for the failure of FBx in identifying CS disease, including mpMRI reader oversight with retrospective identification of a lesion missed on initial review, mpMRI invisible cancers, inaccurate sampling of lesion during FBx due to registration and/or mechanical error, and intralesion Gleason heterogeneity. The mechanism(s) involved in under grading by FBx are not mutually exclusive and the presence of multiple errors can compound to yield inaccurate results. In the 62 cases upgraded to CS PCa by SBx mpMRI identified a lesion within the sextant that showed CS disease in 44 (71%). However, mpMRI failed to identify a lesion within the sextant in 10 cases. mpMRI is not without its limitations with a negative predictive value ranging from 63% to 98% for CS disease. 24, 25 The second mechanism of FBx under grading entailed inaccurate sampling of lesions during FBx. FBx is a challenging technique comprising numerous integrated steps to achieve reliable and correct results. Accuracy may be affected by multiple factors, including precise registration and superimposition of real-time TRUS with previously acquired MRI, mechanical hand-to-eye coordination and steadiness during navigation and needle deployment, and meticulous real-time adjustments for prostate motion/deformation during the procedure. 26 Biopsy mapping and archived imaging review in 25 of 44 patients with sextant overlap revealed 5 with registration error and 8 with mechanical error. However, they represent a small proportion of the entire 1,003 patient biopsy cohort.
Lastly, review of whole mount pathology in the 13 of 25 patients treated with radical prostatectomy revealed intralesion Gleason heterogeneity as the mechanism for Gleason upgrading by SBx over FBx in 10. Histological grade heterogeneity in PCa is a well established concept in the setting of multifocal adenocarcinoma and intratumor heterogeneity. Current practice at our institution is to obtain 2 biopsy cores (axial and sagittal) per lesion. However, there is a potential consideration in saturating lesions (especially larger lesions) with additional cores during FBx to gain the most accurate representation of the Gleason distribution within a lesion. This area is currently under investigation. Sampling larger lesions with additional cores may be achieved with division into subregions of interest or systematic sampling at arbitrary intervals. However, this would be balanced by the morbidity of obtaining additional cores.
There are no tests without shortcomings and it is prudent to evaluate them with a critical eye. mpMRI and FBx missed a number of CS prostate cancers (62 of 564), of which only 2% represented high risk disease. The study findings reveal that the number of cases under graded on FBx could be further reduced by meticulous imaging review to avoid missed lesions and careful attention to biopsy technique. The factors associated with under grading were statistically significant. However, they are unlikely to be clinically meaningful as they are not actionable items in the patient selection for additional SBx due to the number who would require combined FBx/SBx biopsy to capture such a limited number. Strengths of this study include a large patient cohort, a well established, standardized imaging/ biopsy protocol and biopsy mapping with archived biopsy imaging review to infer potential mechanisms of FBx under grading. However, a number of limitations are apparent. It was assumed in patients with sextant overlap that the systematic core that revealed higher risk disease sampled the lesion that was pre-identified in the sextant. It is possible that the systematic core sampled a region in the sextant but outside the lesion, in which case multifocality within the sextant and/or the presence of a MRI invisible lesion could be theoretical reasons for SBx upgrading.
Biopsy mapping and archived biopsy imaging review were only performed in a limited subset of cases upgraded by SBx to CS disease because the technology was not introduced until 2011. Furthermore, biopsy mapping of coordinates onto MRI assumes accurate registration to transpose TRUS coordinates onto MRI. However, several factors such as prostate motion and/or deformation of the prostate during the procedure can affect registration, leading to error. Phantom studies with the UroNav platform have demonstrated that the mean AE SD accuracy of the system is approximately 2.4 AE 1.2 mm.
30 Therefore, there is a small degree of error in mapping needle coordinates based on the accuracy of registration.
Lastly, since to our knowledge no method of objective measurement of registration error is currently integrated into any platform, the presence of registration error and mechanical error was determined by examining archived biopsy imaging at the time of biopsy of the lesion of interest.
CONCLUSIONS
Disease risk category upgrading to CS disease by SBx over FBx occurred in a small proportion of patients. Thus, FBx is highly accurate and identifies most CS disease. Mechanisms of disease risk 
EDITORIAL COMMENT
As urologists move toward making MRI fusion biopsy the standard of care, we must answer the question of whether we can confidently eliminate systematic biopsies. This impressive database review suggests that performing systematic biopsies still has value, albeit in a small number of patients.
Further refinements in MRI interpretation and elimination of registration errors may one day allow us to only biopsy the lesions seen on MRI. It is encouraging that in a large database with more than 1,000 patients there were only 10 (0.1%) with significant lesions that were not visible on MRI. I suspect that the majority of errors in registration occurred early in the learning curve. In our community practice at Minnesota Urology we have performed approximately 900 MRI-fusion biopsies and would vouch for the many ways in which errors can be made (radiologist, registration, urologist technique and patient motion). Systematic biopsies may help mitigate these potential errors until there is adequate radiologist confidence in not missing significant cancers and urologists have mastered the art of performing fusion biopsies.
Basir Tareen
Minnesota Urology St. Paul, Minnesota
REPLY BY AUTHORS
Target-only prostate biopsies may potentially replace the need for systematic biopsies in the future. However, patients with MRI negative results are an under studied population not included in the current cohort and up to 16% of such patients can harbor CS disease. 1 The current study informs a number of important results. Only 8 patients harbored lesions missed on initial review, of which none represented high risk lesions, suggesting that MRI readers can achieve a high degree of accuracy. This will likely continue to improve with the institution of PI-RADS, version 2, which provides standardized criteria for interpretation. 2 Registration error, mechanical error and intralesion Gleason heterogeneity are generally uncommon but we found that they can be potentially addressed with careful attention to technique and an increase in lesion sampling. Whether saturation sampling of a lesion may further reduce under detection of CS prostate cancer and potentially further limit the need for systematic biopsy remains to be seen. The variable negative predictive value of MRI, in addition to the 6.2% of patients with positive magnetic resonance findings who were upgraded to CS prostate cancer, suggests a continuing role for systematic sampling. 
